Funding for this research was provided by:
Else Kröner-Fresenius-Stiftung (2018_EKES.04)
Universitätsklinikum Hamburg-Eppendorf (UKE)
Article History
Received: 16 February 2023
Accepted: 1 April 2023
First Online: 17 April 2023
Declarations
:
: CB received a grant from the Hilde-Ulrichs-Stiftung, served on scientific advisory boards for Bial, Hormosan Pharma, Merz Pharmaceuticals and Zambon and received honoraria for lectures from Abbvie, Bial, Stada Pharma, TAD Pharma, UCB Pharma and Zambon. MU has nothing to declare. TM has nothing to declare. CUC reports personal fees from Desitin, Pfizer and Zambon outside the submitted work.